Previous close | 107.00 |
Open | 107.00 |
Bid | 86.15 |
Ask | 90.95 |
Strike | 60.00 |
Expiry date | 2026-01-16 |
Day's range | 107.00 - 107.00 |
Contract range | N/A |
Volume | |
Open interest | 260 |
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared with its previously approved bivalent COVID-19 vaccine.
Long term investing can be life changing when you buy and hold the truly great businesses. And highest quality...
Moderna revealed its combination flu/COVID vaccine performed better than the two shots independently.